Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential.
Initial studies had highlighted a possible link between DTG and neural tube defects (birth defects of the brain and spinal cord that cause conditions such as spina bifida) in infants born to women using the drug at the time of conception. This potential safety concern was reported in May 2018 from a study in Botswana that found 4 cases of neural tube defects out of 426 women who became pregnant while taking DTG. Based on these preliminary findings, many countries advised pregnant women and women of childbearing potential to take efavirenz (EFV) instead.
New data from two large clinical trials comparing the efficacy and safety of DTG and EFV in Africa have now expanded the evidence base. The risks of neural tube defects are significantly lower than what the initial studies may have suggested. DTG is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used. DTG also has a high genetic barrier to developing drug resistance, which is important given the rising trend of resistance to EFV and nevirapine-based regimens. In 2019, 12 out of 18 countries surveyed by WHO reported pre-treatment drug resistance levels exceeding the recommended threshold of 10%.
WHO press release: https://www.who.int/news-room/detail/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations
WHO Guideines 2019: https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf
Dear Colleague,
Are you attending the EDCTP 2025 forum in Kigali (Rwanda)?
Don't miss the Communications workshop on Thursday 19 June (15:30 - 17:30 Rwanda time) in room MH3.
The topic of the workshop will be: "From good to great: Mastering communication skills for impactful science
Best,
The EDCTP team.
Dear Stakeholder
Science Forum South Africa 2025 (SFSA 2025) will take place from 24 to 28 November 2025 at the CSIR International Convention Centre (CSIR ICC) in Pretoria, South Africa. This year marks the tenth edition of SFSA, celebrating a decade of igniting vibrant discussions on the role of science in society. The Forum brings together stakeholders from the scientific community, government, industry, and civil society.
We are pleased to invite proposals from individuals and institutions to convene panel sessions as part of the SFSA 2025 programme. These sessions should align with the Forum's theme and sub-themes, and provide an opportunity to engage diverse perspectives in critical conversations.
Igniting Conversations: Placing Science, Technology, and Innovation at the Centre of Government, Education, Society, and Industry
The deadline for proposal submissions is 21 July 2025.
SFSA 2025 is proudly co-hosted by the South African Department of Science, Technology and Innovation (DSTI) and the Science Diplomacy Capital for Africa (SDCfA) initiative.
We look forward to your participation in shaping the dialogue at SFSA 2025.
Best regards
The SFSA 2025 Organising Committee
📢Exciting news for early career researchers and PhD
students planning to attend the ISV congress in South Africa from 28-30 October 2025!
Applications deadline for awards to attend the congress
has been extended to 7 April 2025.
The award for LMIC members covers:
✨ISV
congress registration fee
✨Accommodation
for up to 4 nights
✨Economy
class air travel
To apply, visit: https://www.isvcongress2025.co.za/
Read more